Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Clinical Significance of Facet Cysts in Patients Undergoing Lumbar Decompression for Degenerative Spine
Hudson, Miles , Safdar, Aleeza , Krauss, William E. , Kalani, Maziyar A. , Chen, Selby G. , Bydon, Mohamad , Hudson, Miles A, Krauss, William, Kalani, Maziyar, Bakhsheshian, Joshua , Nathani, Karim Rizwan , Chen, Selby , Abode-Iyamah, Kingsley

Clinical Spine Surgery | August 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/bsd.0000000000001900 | PMID 40838617 Get It

Study design: Cohort study. Objective: This study aimed to evaluate influence of facet cysts on outcomes in patients undergoing lumbar decompression, and the influence of spinal fusion in patients undergoing decompression for facet cysts. Summary of Background Data: The impact of facet cysts on outcomes following lumbar spine surgery for degenerative spine disease remains unclear. Methods: Our multicenter institutional Neurosurgery Enterprise Registry was queried for patients who underwent lumbar decompression for degenerative spine conditions. Patients were divided into 2 cohorts: those with lumbar spine facet cysts and those without. Retrospective propensity-score matching was performed using 13 baseline variables to adjust for potential confounding factors, including age, sex, race, body mass index, and comorbidities. Secondary analysis comparing outcomes in patients with facet cysts cases undergoing decompression only versus those undergoing decompression and fusion was conducted. Results: A total of 6768 patients were reviewed, of which 188 (2.8%) had facet cysts, which underwent lumbar decompression during 2019–2023. After 3:1 matching, patients with facet cysts were compared with 564 patients without it. We found no significant differences in LOS, nonroutine discharge, postoperative complications, readmissions, and reoperations. In addition, in cases with facet cysts, decompression reported no increased risk for discharge opioids, readmissions, and reoperations, whereas fusion (in a separate cohort of 127 patients with facet cysts) was associated with an increased risk for nonroutine discharge (3.7% vs. 10.2%, P=0.021), complications (2.1% vs. 7.1%, P=0.042), and longer LOS (0.89±1.69 vs. 3.74±2.03 d, P<0.001) and operative time (138.78±62.99 vs. 273.07±111.51 min, P <0.001). Conclusions: The presence of facet cysts does not significantly affect outcomes of lumbar decompression for degenerative spine disease. Decompression alone for facet cysts can have better outcomes than decompression and fusion. The need for fusion should be weighted with its higher risks of complications, longer hospital stays, and nonroutine discharges.
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Lurz, Philipp , Hahn, Rebecca T. , Kodali, Susheel , Makkar, Raj , Sharma, Rahul , Davidson, Charles J. , O’Neill, Brian , Yadav, Pradeep , Zahr, Firas , Chadderdon, Scott , Eleid, Mackram F. , Smith, Robert L, Garcia, Santiago , Kister, Tobias , Kipperman, Robert, Lim, Scott, Hermiller, James, Mishell, Jacob M. , Rassi, Andrew N., Szeto, Wilson Y. , Babaliaros, Vasilis , Barker, Colin M. , Summers, Matthew , Chetcuti, Stanley, Ailawadi, Gorav , Russo, Mark, Rinaldi, Michael, Chehab, Bassem , Nickenig, Georg, Stinis, Curtiss, Inglessis‐Azuaje, Ignacio , Dhoble, Abhijeet , Petrossian, George , Shah, Pinak, Staniloae, Cezar , Nores, Marcos, Singh, Gagan D. , Baldus, Stephan , Rudolph, Volker , Barb, Ilie, Klodell, C.T., Gray, William A. , Strote, Justin A, Sannino, Anna , Grayburn, Paul , Mack, Michael J. , Leon, Martin B. , Thourani, Vinod H. , Lim, D. Scott , Szerlip, Molly , Kister, Tobias , Lim, D Scott , Saxon, John , Kapadia, Samir , Mishell, Jacob M , Herrmann, Howard C , Hausleiter, Jörg , Babaliaros, Vasilis , Barker, Colin M , Lindman, Brian R , Latib, Azeem , von Bardeleben, Ralph Stephan , Summers, Matthew , Ailawadi, Gorav , Rinaldi, Michael , Chehab, Bassem M , Nickenig, Georg , Inglessis-Azuaje, Ignacio , Dhoble, Abhijeet , Chhatriwalla, Adnan K , Petrossian, George , Shah, Pinak , Staniloae, Cezar , Williams, Mathew , McCabe, James M , Singh, Gagan , Baldus, Stephan , Rudolph, Volker , Klodell, Charles , Gray, William , Strote, Justin , Sannino, Anna , Grayburn, Paul , Mack, Michael J , Thourani, Vinod H , Davidson, Charles J. , Hahn, Rebecca T , Lurz, Philipp , Smith, Robert L, Whisenant, Brian K. , Kapadia, Samir , Hausleiter, Jörg , Lindman, Brian R. , Latib, Azeem , Muhammad, Kamran I. , Williams, Mathew

European Heart Journal | August 21, 2025 | Volume: 47 | Issue: 17 | Pages: 2059-2073

10.1093/eurheartj/ehaf676 | PMID 40878717 Get It

Abstract Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
Human obesity decreases the anti-inflammatory functionality of adipose tissue–derived mesenchymal stem/stomal cells by upregulating IL-1β expression
Xing, A., Zhu, Xiangyang , Lü, Bo , Saeedi, Mina Al, Lerman, Amir, Eirin, Alfonso , Lerman, Lilach O. , Lerman, Amir , Al Saeedi, Mina, Lerman, Amir , Eirin, Alfonso , Lerman, Lilach O , Xing, Li, Klomjit, Nattawat

Stem Cells | August 21, 2025 | Volume: 43 | Issue: 12 | Pages: No page available

10.1093/stmcls/sxaf058 | PMID 40839167 Get It

Abstract Importance Mesenchymal stromal cells (MSCs) possess therapeutic properties that mediate repair. Obesity impairs MSC functionality and therapeutic efficacy, possibly by eliciting dynamic modifications of epigenetic markers, like 5-hydroxymethylcytosine (5hmC). Objective We hypothesized that human obesity alters the 5hmC landscape and anti-inflammatory capacity of adipose tissue-derived MSCs to activate the prominent inflammatory signaling mediator Interleukin (IL)-1β. Design, Setting, Participants, Intervention Adipose tissue samples were collected from obese and lean individuals (body mass index ≥30 or &lt;30 kg/m2, respectively, n = 11 each) during weight-loss or kidney donation surgery. Main Outcomes and Measures MSCs were harvested and analyzed for 5hmC profiles (MeDIP-seq) and mRNA expression (RNA-seq) (n = 5 each). Subsequently, MSCs or a vehicle were injected into mice, (n = 6 each) and two-weeks later, kidneys were evaluated using in-vivo magnetic resonance imaging and ex vivo studies. The role of IL-1β was then studied in-vitro in MSC-induced immunomodulation using siRNA in macrophages. Results Compared to MSC from lean patients, obese-MSC genes showed 2087 differential 5hmC modifications and 175 differential mRNA expression. Among them, 14 genes with overlapping alterations were involved in regulation of cytokine production, prominently IL-1β. Injecting obese MSCs elevated renal expression of IL-1β and M1 macrophage count but lowered kidney perfusion. Silencing IL-1β in obese-MSCs in vitro reduced M1 phenotype switching in co-incubated macrophages. Conclusions and Relevance Obesity induces epigenetic and gene expression changes in MSCs, particularly in IL-1β, associated with impaired anti-inflammatory functionality of MSCs. Targeting IL-1β could be a useful therapeutic approach to modulate the decline in MSC functionality resulting from obesity.
A Rat Model of Second Impact Syndrome in Diffuse Traumatic Brain Injury: Evidence of Facial Hypersensitivity, Neurological and Other Behavioral Alterations, and Immunological and Histopathological Tissue Changes
Aragão, Ana Carolina A., Santos, Vito Thayson dos, Alencar, Denise, Mendes, Gabriel Cury Batista, Pontes, Lucca de, Sanchez-Garavito, Emiliano, Wilding, Hannah , Lima, Roberto C.A., Nobre, Lívia Maria Soares , Melo, Juliana, Oliveira, Denise Nunes , Rolim, Adriana, Filho, Leonardo de Macêdo , Mendes, Gabrielle, Bhanja, Debarati , Lima, Roberto Cesar, Melo, Juliana, Shlobin, Nathan A. , Sessle, Barry J. , Hawryluk, Gregory W. J.

No container title available | August 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7273712/v1 Get It

Abstract Traumatic brain injury (TBI) can lead to chronic complications, including headache and facial hypersensitivity. Second-impact syndrome (SIS), occurring when a second TBI precedes recovery from an initial injury, often causes severe long-term symptoms. Neuroinflammation is implicated, but the comprehensive pathophysiology of SIS remains unclear. This study characterized neurological/behavioral outcomes, facial nociception, plasma inflammatory markers, and central nervous system (CNS) histopathology in rat models of SIS and single mild TBI. Female Wistar rats (n = 6/group) were assigned to naïve control, sham surgery, single impact (TBI), or double impact (SIS; intervals: 1h, 24h, 3d, 7d, 14d). Mild TBI was induced using a modified Marmarou weight-drop model. Assessments (facial mechanical sensitivity via von Frey, Neurological Severity Scale (NSS), Neurobehavioral Scale (NBS)) were performed pre-injury and on days 1,3,5,7 post-injury. Plasma IL-6 and TNF-α were measured by ELISA. Histopathology (H&E) assessed CNS inflammation. All impact groups developed transient facial mechanical allodynia and acute neurobehavioral deficits (impaired NSS/NBS at day 1). SIS groups, particularly with longer intervals (≥ 24h), exhibited more prolonged facial allodynia and significant neurological deficits compared to single TBI at specific timepoints. Plasma cytokines showed minimal changes. Histopathology revealed significantly elevated CNS inflammation in both TBI and SIS groups versus controls, with SIS groups (intervals 24h-14d) showing robust responses. Repeated TBI, especially with longer recovery intervals between injuries, results in more severe and prolonged facial allodynia, neurological deficits, and CNS neuroinflammation than a single mild TBI. These findings illuminate SIS pathophysiology and underscore the critical need for protection post-concussion.
Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study
Tepper, Stewart J. , Doležil, David, Gil‐Gouveia, Raquel , Lucas, Christian , Piasecka‐Stryczynska, Karolina , Mikol, Daniel D., Chehrenama, Mahan, Chou, Denise E. , Liu, Zilu , Dodick, David W. , Lantéri‐Minet, Michel , Szabó, Gyöngyi, Lima, Gabriel Paiva da Silva

European Journal of Neurology | August 21, 2025 | Volume: 32 | Issue: 8 | Pages: No page available

10.1111/ene.70328 | PMID 40838472 Get It

ABSTRACTBackgroundErenumab‐induced medication overuse headache (MOH) remission in participants with chronic migraine (CM) in a prospective, Phase 4, randomized, placebo‐controlled trial with an open‐label treatment period (OLTP). We present 1‐year results from the combined double‐blind treatment period (DBTP) and OLTP for the stratified nonopioid cohort.MethodsParticipants with CM‐MOH were randomized 1:1:1 to subcutaneous 70 or 140 mg erenumab every 4 weeks (QM) or placebo for the initial 24 weeks (DBTP). Those successfully completing DBTP could continue the 28‐week OLTP, maintaining the same erenumab dose received during DBTP or, if receiving placebo, randomly assigned 1:1 to erenumab 70 or 140 mg QM. OLTP endpoints were exploratory.ResultsOverall, 552 participants received erenumab (70 mg, n = 274; 140 mg, n = 278); 95.3% completed OLTP. One‐year MOH relapse in participants who achieved MOH remission at DBTP Month 6 was 2.7% (3/111) and 2.4% (3/124) with erenumab 70 and 140 mg, respectively; absence of MOH at study end was observed in 69.0% (189/274) and 75.5% (210/278) of participants. Sustained MOH absence over 1 year was reported in 60.5% (107/177) and 68.8% (119/173) of participants, respectively. Sustained improvements in measures of headache days, medication days, and function were observed in both groups. No new safety concerns were identified (grade ≥ 3, 35 [6.3%]; serious, 17 [3.1%]; adverse events leading to treatment discontinuation, 5 [0.9%]).ConclusionsErenumab was effective in inducing and sustaining MOH remission and improving function over 1 year. Treatment compliance remained high, with safety events consistent with erenumab's known safety profile.Trial RegistrationNCT03971071
Regional Variations in the Management and Outcomes of Pulmonary Embolism: A Five‐Year United States Analysis
Mehta, Aryan , Bansal, Mridul , Ahmad, Khansa , Ingrassia, Joseph, Abbott, J. Dawn, Vallabhajosyula, Saraschandra , Ahmad, Khansa , Vallabhajosyula, Saraschandra , Mehta, Aryan , Nagaraja, Vinayak

Catheterization and Cardiovascular Interventions | August 21, 2025 | Volume: 106 | Issue: 4 | Pages: 2632-2636

10.1002/ccd.70110 | PMID 40838428 Get It

ABSTRACT Background Acute pulmonary embolism (PE) is one of the most common causes of cardiovascular mortality in the United States. Significant variations in the management of various cardiovascular conditions have previously been reported, but this has been poorly elucidated for pulmonary embolism. Methods During 2016–2020, adult (≥ 18 years) nonelective admissions with PE, admitted to Northeast, Midwest, South, and West geographic regions were identified using the National Inpatient Sample. Outcomes of interest included in‐hospital mortality, utilization of PE therapies, non‐cardiac organ support, total hospitalization costs, and hospitalization duration. Results In this 5‐year duration, 904,260 admissions were identified ‐ Northeast, Midwest, South, and West had 166,050 (18.3%), 225,680 (24.9%), 350,160 (38.7%), and 162,370 (17.9%) admissions, respectively. On average, admissions to the Northeast were less comorbid, from a higher socioeconomic status, privately insured, and more commonly admitted to urban teaching and medium‐sized hospitals (all p < 0.001). The Northeast region also had the lowest rates of definitive PE therapies except surgical thrombectomy. In comparison to the Northeast, the in‐hospital mortality was higher in the South and West and lower in the Midwest region (3.1% vs 2.8% vs 3.2% vs 3.3%, p < 0.001). However, on adjusted analysis with Northeast as a reference, in‐hospital mortality was noted to be lower in the Midwest (adjusted odds ratio [aOR] 0.98, 95% confidence interval [CI] 0.67−0.84; p < 0.001), South (aOR 0.89, 95% CI 0.80−0.98; p < 0.05), and the West (aOR 0.88, 95% CI 0.78−0.99; p < 0.05). Conclusion In this study, we noted significant heterogeneity in the management and outcome of pulmonary embolism across various regions of the United States.
State‐of‐the‐art management of Dravet syndrome
Vasquez, Alejandra , Wirrell, Elaine , Wirrell, Elaine C

Developmental Medicine & Child Neurology | August 21, 2025 | Volume: 67 | Issue: 12 | Pages: 1527-1535

10.1111/dmcn.16475 | PMID 40836583 Get It

Abstract Dravet syndrome is a severe developmental and epileptic encephalopathy caused by heterozygous, loss‐of‐function, pathogenic variants in the SCN1A gene. It is characterized by frequent, often prolonged convulsive seizures. Dravet syndrome is associated with diverse comorbid conditions, including developmental impairment, intellectual disability, and behavioral disturbances, in addition to high mortality rates. Prompt diagnosis and treatment initiation are essential to reduce seizure frequency, status epilepticus, and potentially improve neurodevelopmental outcomes. Currently available therapies such as fenfluramine, stiripentol, and cannabidiol have demonstrated significant reduction in convulsive seizure frequency, based on randomized controlled trials and real‐world studies; however, they have not markedly affected non‐seizure symptoms. Emerging therapies such as genetic modulation are promising given their potential for disease modification, seizure frequency reduction, and improvement of non‐seizure outcomes. This review of observational studies and randomized clinical trials provides an overview of the natural history of Dravet syndrome, current treatment guidelines with recently approved medications, addressing both safety and efficacy, and new therapeutic approaches, including disease‐modifying therapies. The therapeutic landscape in Dravet syndrome is evolving, with the use of new antiseizure agents and precision therapies that target the SCN1A variant. Goals of treatment include improvement of seizure burden, neurodevelopment, comorbidities, and quality of life in individuals with Dravet syndrome.
A Systematic Approach to Screen, Identify, and Correct Malfunctioning Interruptive Alerts
Wahsh, EzzAddin Al, Eichenlaub, Carol, Holbrook, Courtney, Juskewitch, Justin, Wahsh, EzzAddin Al, Juskewitch, Justin E. , Holbrook, Courtney, Caraballo, Pedro J.

Applied Clinical Informatics | August 20, 2025 | Volume: 16 | Issue: 04 | Pages: 863-871

10.1055/a-2646-6297 | PMID 40835228 Get It

AbstractInterruptive alerts can negatively impact clinical workflows and contribute to alert fatigue, provider frustration, and burnout. Given that interruptive alert overriding is a heterogeneous and recurring phenomenon, occurring across different organizational contexts with varying characteristics and circumstances, we hypothesize a pragmatic approach with multimodal interventions to address malfunctioning alert populations and maintain those contributing to better patient care.This study aimed to develop a systematic approach to screen, identify, and correct malfunctioning interruptive alerts within a tertiary healthcare system.We performed screening by assessing the alert population, exploring available resources, and defining alert population inclusion and exclusion criteria. We identified interruptive alerts and then conducted an exploratory analysis. We shared insights from discussions with our expert panel to validate our findings and find gaps in current alert monitoring. We then performed focus groups and interviews as part of a root cause analysis. To address the findings of these investigations, we prioritized which alerts to improve, evaluated solutions, and recommended steps to improve our governance structure.We developed an approach to assess around 1,500 unique alerts in a tertiary center from January to June 2023. We introduced two approaches to visually analyze alert populations: alert-focused analysis and people- and systems-focused analysis. We utilized an expert panel to further enhance the power and speed of alert evaluation and then investigated one emerging alert with focus groups, identifying root causes for its malfunction. This alert demonstrated how enterprise practice changes, coupled with design and cultural issues, can trigger significant alert malfunctions.A multi-modal intervention approach is needed to evaluate interruptive alerts and act quickly on findings. Utilizing both analytical and nonanalytical methods can work in synergy to facilitate this framework. Such approaches may reduce time and be valuable tools for optimally allocating resources to tackle institutional alert challenges.
DataMorpher: Automatic Data Transformation Using LLM-Based Zero-Shot Code Generation
Sharma, Ankita , Tandel, Jaykumar , Li, Xuanmao, Zhang, Liang , Naqvi, Syed Arsalan Ahmed , Zou, Jia , Wang, Lanjun , Fariha, Anna , Riaz, Irbaz Bin , Cao, Lei

2025 IEEE 41st International Conference on Data Engineering (ICDE) | August 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: 4536-4539

10.1109/icde65448.2025.00346 Get It